Premium
Implications of detecting serum monoclonal protein by MASS‐fix following stem cell transplantation in multiple myeloma
Author(s) -
Abeykoon Jithma P.,
Murray David L.,
Murray Isaiah,
Jevremovic Dragan,
Otteson Gregory E.,
Dispenzieri Angela,
Arendt Bonnie K.,
Dasari Surendra,
Gertz Morie,
Gonsalves Wilson I.,
Kourelis Taxiarchis V.,
Muchtar Eli,
Dingli David,
Warsame Rahma,
Go Ronald S.,
Lacy Martha Q.,
Leung Nelson,
Buadi Francis,
Lin Yi,
Kyle Robert A.,
Rajkumar Vincent,
Kumar Shaji,
Kapoor Prashant
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17195
Subject(s) - multiple myeloma , autologous stem cell transplantation , medicine , minimal residual disease , bone marrow , stem cell , transplantation , oncology , flow cytometry , immunology , biology , genetics
Summary Measurable residual disease (MRD) assessment by marrow‐based next‐generation flow cytometry (NGF) following autologous stem cell transplantation (ASCT) may lead to false‐negative results due to patchy marrow involvement and extramedullary disease in patients with multiple myeloma. We assessed the value of simultaneous MRD evaluation with NGF and serum matrix‐assisted laser desorption ionization time‐of‐flight mass spectrometry (MASS‐FIX). Of all 61 complete responders who were NGF‐negative for MRD, around day‐100 post ASCT, 59% were MASS‐FIX‐positive. At median follow‐up of 26 months, 69% of MASS‐FIX(+)/NGF(−) patients were alive and progression‐free versus 96% of MASS‐FIX(‐)/NGF(−) patients, P = 0·02. MASS‐FIX, a simple peripheral blood‐based assay complements marrow‐based NGF to accurately prognosticate patients with myeloma.